BRPI0618705B8 - anticorpos antagonistas humanizados direcionados contra peptídeo relacionado ao gene da calcitonina, composição farmacêutica e uso dos mesmos - Google Patents

anticorpos antagonistas humanizados direcionados contra peptídeo relacionado ao gene da calcitonina, composição farmacêutica e uso dos mesmos

Info

Publication number
BRPI0618705B8
BRPI0618705B8 BRPI0618705A BRPI0618705A BRPI0618705B8 BR PI0618705 B8 BRPI0618705 B8 BR PI0618705B8 BR PI0618705 A BRPI0618705 A BR PI0618705A BR PI0618705 A BRPI0618705 A BR PI0618705A BR PI0618705 B8 BRPI0618705 B8 BR PI0618705B8
Authority
BR
Brazil
Prior art keywords
antibodies directed
pharmaceutical composition
directed against
related peptide
calcitonin gene
Prior art date
Application number
BRPI0618705A
Other languages
English (en)
Portuguese (pt)
Inventor
Rosenthal Arnon
Pons Jaume
Zeller Joerg
Todd Poulsen Kristian
Jones Collier Sierra
Noubia Abdiche Yasmina
Original Assignee
Labrys Biologics Inc
Rinat Neuroscience Corp
Teva Pharmaceuticals Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37909474&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0618705(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Labrys Biologics Inc, Rinat Neuroscience Corp, Teva Pharmaceuticals Int Gmbh filed Critical Labrys Biologics Inc
Publication of BRPI0618705A2 publication Critical patent/BRPI0618705A2/pt
Publication of BRPI0618705B1 publication Critical patent/BRPI0618705B1/pt
Publication of BRPI0618705B8 publication Critical patent/BRPI0618705B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
BRPI0618705A 2005-11-14 2006-11-02 anticorpos antagonistas humanizados direcionados contra peptídeo relacionado ao gene da calcitonina, composição farmacêutica e uso dos mesmos BRPI0618705B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73662305P 2005-11-14 2005-11-14
US60/736,623 2005-11-14
PCT/IB2006/003181 WO2007054809A2 (en) 2005-11-14 2006-11-02 Antagonist antibodies directed against calcitonin gene-related peptide and methods using same

Publications (3)

Publication Number Publication Date
BRPI0618705A2 BRPI0618705A2 (pt) 2011-09-06
BRPI0618705B1 BRPI0618705B1 (pt) 2018-02-06
BRPI0618705B8 true BRPI0618705B8 (pt) 2021-05-25

Family

ID=37909474

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0618705A BRPI0618705B8 (pt) 2005-11-14 2006-11-02 anticorpos antagonistas humanizados direcionados contra peptídeo relacionado ao gene da calcitonina, composição farmacêutica e uso dos mesmos

Country Status (38)

Country Link
US (20) US8007794B2 (Direct)
EP (6) EP3178493A1 (Direct)
JP (1) JP5123197B2 (Direct)
KR (2) KR20080068062A (Direct)
CN (2) CN103421114B (Direct)
AP (1) AP2008004467A0 (Direct)
AU (1) AU2006313434B2 (Direct)
BE (1) BE2019C521I2 (Direct)
BR (1) BRPI0618705B8 (Direct)
CA (1) CA2626120C (Direct)
CR (1) CR9975A (Direct)
CU (1) CU23872B1 (Direct)
CY (3) CY1120249T1 (Direct)
DK (3) DK3045182T3 (Direct)
EA (1) EA015526B1 (Direct)
EC (1) ECSP088451A (Direct)
ES (3) ES2664421T3 (Direct)
GE (1) GEP20115333B (Direct)
HR (2) HRP20180753T1 (Direct)
HU (3) HUE036940T2 (Direct)
IL (3) IL190876A (Direct)
LT (3) LT3045182T (Direct)
LU (2) LUC00119I2 (Direct)
MA (1) MA30136B1 (Direct)
ME (1) ME00419B (Direct)
MY (1) MY153249A (Direct)
NL (1) NL300997I2 (Direct)
NO (3) NO344099B1 (Direct)
NZ (1) NZ568237A (Direct)
PL (3) PL3045182T3 (Direct)
PT (3) PT1957106E (Direct)
RS (3) RS20080200A (Direct)
SI (3) SI2380592T1 (Direct)
SV (1) SV2008002905A (Direct)
TN (1) TNSN08213A1 (Direct)
UA (1) UA94244C2 (Direct)
WO (1) WO2007054809A2 (Direct)
ZA (1) ZA200803484B (Direct)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS20080200A (sr) 2005-11-14 2009-07-15 Rinat Neuroscience Corp., Antagonistička antitela usmerena protiv kalcitonina, peptida povezanog sa genom, i postupak njihovog korišćenja
US8293239B2 (en) 2008-03-04 2012-10-23 Pfizer Limited Methods of treating chronic pain
MX2010009724A (es) * 2008-03-04 2010-09-28 Pfizer Ltd Procedimientos de tratamiento del dolor inflamatorio-.
AU2009234159B2 (en) 2008-04-09 2013-12-19 Pherin Pharmaceuticals, Inc. Steroid treatment for hot flashes
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
US8491016B2 (en) 2009-03-16 2013-07-23 Colder Products Company Aseptic coupling devices
CA2771186C (en) 2009-08-28 2018-01-02 Rinat Neuroscience Corporation Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
AR081434A1 (es) * 2010-06-10 2012-08-29 Lilly Co Eli Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US12533312B2 (en) 2011-02-04 2026-01-27 Seed Health, Inc. Method and system for preventing sore throat in humans
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
BR122014031521B1 (pt) 2011-02-10 2022-08-23 Velos Media International Limited Dispositivo e método de processamento de imagem
RS58621B1 (sr) * 2011-05-20 2019-05-31 Alderbio Holdings Llc Anti-cgrp kompozicije i njihova upotreba
NZ732970A (en) 2011-05-20 2022-08-26 H Lundbeck As Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
JP6189832B2 (ja) * 2011-05-20 2017-08-30 アルダーバイオ・ホールディングズ・エルエルシー 慢性および急性の下痢を治療または予防するための抗ｃｇｒｐ若しくは抗ｃｇｒｐ−ｒの抗体または抗体断片の使用
JP6025871B2 (ja) * 2012-01-26 2016-11-16 クリストファー ジェイ． ソアレス ペプチドホルモンのカルシトニンｃｇｒｐファミリーのペプチドアンタゴニスト及びその使用
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
TWI712419B (zh) * 2013-07-03 2020-12-11 美商艾爾德生物製藥股份有限公司 使用抗ｃｇｒｐ抗體之葡萄糖代謝的調節
CN109973730B (zh) 2013-07-23 2021-01-12 可得制品公司 无菌联接装置
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
KR102274964B1 (ko) 2014-03-21 2021-07-09 테바 파마슈티컬스 인터내셔널 게엠베하 칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
JP2017515852A (ja) * 2014-05-16 2017-06-15 ソーク インスティテュート フォー バイオロジカル スタディーズ 代謝障害を処置するための組成物および方法
US12053630B2 (en) 2014-08-17 2024-08-06 Coloplast A/S Implantable pulse generator with automatic jump-start
EP3180069B1 (en) 2014-08-17 2020-05-13 Nine Continents Medical, Inc. Miniature implatable neurostimulator system for sciatic nerves and their branches
CA2960756C (en) * 2014-09-15 2023-08-01 Amgen Inc. Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
JO3669B1 (ar) * 2015-01-06 2020-08-27 Ferring Bv بيبتيدات مضَادَّة لببتيد المرتبط بجين الكالسيتونين
JOP20200116A1 (ar) * 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
MX2018003713A (es) * 2015-09-24 2018-08-15 Teva Pharmaceuticals Int Gmbh Prevencion, tratamiento y reduccion del dolor de cabeza postraumatico (persistente).
US20190031748A1 (en) * 2016-01-28 2019-01-31 Eli Lilly And Company Cgrp antibodies and uses thereof
EP3411066A1 (en) 2016-02-01 2018-12-12 Eli Lilly and Company Parathyroid hormone anti-rankl antibody fusion compounds
KR20190005873A (ko) 2016-04-15 2019-01-16 앨더 바이오파마슈티컬즈, 인코포레이티드 항-pacap 항체 및 그의 용도
MX392628B (es) * 2016-07-25 2025-03-24 Cephalon Inc Amortiguador de lavado de cromatografia de afinidad.
CN109922820A (zh) 2016-09-02 2019-06-21 克里斯托弗·J·索尔斯 Cgrp受体拮抗剂在神经保护和神经系统疾病中的应用
US20180111984A1 (en) * 2016-09-23 2018-04-26 Teva Pharmaceuticals International Gmbh Treating cluster headache
FI3515937T3 (fi) 2016-09-23 2026-02-11 Teva Pharmaceuticals Int Gmbh Refraktaarisen migreenin hoito
CN106442967B (zh) * 2016-09-27 2018-05-15 鸿运华宁（杭州）生物医药有限公司 一种检测跨膜蛋白单克隆抗体亲和力的方法
GB2557655A (en) 2016-12-14 2018-06-27 Teva Pharma Medical injection device packaging
AU2018226811A1 (en) 2017-03-02 2019-09-26 Beth Israel Deaconess Medical Center, Inc. Selecting headache patients responsive to antibodies directed against calcitonin gene related peptide
WO2018236873A1 (en) * 2017-06-19 2018-12-27 President And Fellows Of Harvard College Methods and compositions for treating a microbial infection
US11426706B2 (en) 2017-06-21 2022-08-30 Cephalon, Inc. Cation exchange chromatography wash buffer
AR114080A1 (es) 2018-01-12 2020-07-22 Amgen Inc Anticuerpos pac1 y sus usos
US11629184B2 (en) * 2018-02-23 2023-04-18 Remd Biotherapeutics, Inc. Calcitonin gene-related peptide (CGRP) antagonist antibodies
US11295402B2 (en) 2018-03-28 2022-04-05 Bank Of America Corporation Blockchain-based property repair
US10498808B2 (en) 2018-03-28 2019-12-03 Bank Of America Corporation Blockchain-based property management
US11475422B2 (en) 2018-03-28 2022-10-18 Bank Of America Corporation Blockchain-based property management
WO2019195185A1 (en) 2018-04-02 2019-10-10 Amgen Inc. Erenumab compositions and uses thereof
US10899826B1 (en) 2018-09-13 2021-01-26 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for an anti-CGRP antagonist antibody
MX2021003329A (es) 2018-09-20 2021-06-08 Teva Pharmaceuticals Int Gmbh Resorte de inyección para jeringa precargada desgastada e inyector automático.
TWI769424B (zh) * 2018-12-31 2022-07-01 美商Ｕｎｓ Ｉｐ控股公司 針對降鈣素基因相關胜肽（ｃｇｒｐ）的胜肽免疫原及其用於預防和治療偏頭痛的製劑
PH12021551478A1 (en) 2019-01-08 2022-05-02 H Lundbeck As Acute treatment and rapid treatment of headache using anti-cgrp antibodies
JP2022546706A (ja) 2019-08-27 2022-11-07 コルダー プロダクツ カンパニー 使い捨てジェンダーレス無菌性流体継手
AU2020346186A1 (en) * 2019-09-09 2022-04-07 Seurat Therapeutics Combination therapy for the treatment of migraines
AU2020202454A1 (en) 2020-04-06 2021-10-21 H. Lundbeck A/S Treatment of most bothersome symptom (MBS) associated with migraine using anti-CGRP antibodies
CN112274302B (zh) * 2020-11-24 2021-07-13 四川大学华西医院 一种多单元可调的智能化椎间融合器
IT202000029459A1 (it) * 2020-12-03 2022-06-03 Alberto Chiarugi Terapia dei disturbi emotivi
MX2023010115A (es) 2021-03-02 2023-11-09 Cgrp Diagnostics Gmbh Tratamiento y/o reducción de la aparición de la migraña.
WO2023026205A1 (en) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Preventative treatment of migraine
US20250099561A1 (en) * 2022-01-21 2025-03-27 Luis Hector BARBEITO ERBA Active immunization for reducing osteoarthritic, neuropathic, and cancer pain
KR20240153599A (ko) 2022-02-28 2024-10-23 트리뎀 바이오사이언스 게엠베하 & 씨오 케이지 적어도 β-글루칸 또는 만난으로 구성되거나 또는 이를 포함하는 접합체
CN121285662A (zh) * 2023-05-04 2026-01-06 阿雷克森制药公司 高通量Fab抗体片段生成和排序

Family Cites Families (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JPS62129297A (ja) * 1985-08-09 1987-06-11 Toyo Jozo Co Ltd カルシトニン遺伝子関連ペプチド誘導体
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US4814567A (en) 1987-07-08 1989-03-21 Darko Jorge Lazaneo Dragicevic Electro-thermic resonance system for heating liquid
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
DE69034078T2 (de) 1989-03-21 2004-04-01 Vical, Inc., San Diego Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
DK0479909T3 (da) 1989-06-29 1997-04-07 Medarex Inc Bispecifikke reagenser til AIDS-behandling
CA2020786A1 (en) 1989-07-10 1991-01-11 Amylin Pharmaceuticals, Inc. Treatment of obesity and essential hypertension and related disorders
EP0487587A1 (en) 1989-08-18 1992-06-03 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
NZ237464A (en) 1990-03-21 1995-02-24 Depotech Corp Liposomes with at least two separate chambers encapsulating two separate biologically active substances
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE69233254T2 (de) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanisierter Heregulin Antikörper
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
ATE237694T1 (de) 1991-08-20 2003-05-15 Us Gov Health & Human Serv Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
CA2119930C (en) 1991-09-23 2002-10-01 Hendricus R. J. M. Hoogenboom Production of chimeric antibodies - a combinatorial approach
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
AU3144193A (en) 1991-11-21 1993-06-15 Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
DE4143639C2 (de) 1991-12-02 2002-10-24 Qiagen Gmbh Verfahren zur Isolierung und Reinigung von Nukleinsäuren
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JPH07507689A (ja) 1992-06-08 1995-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 特定組織のターゲティング方法及び組成物
CA2137361A1 (en) 1992-06-10 1993-12-23 W. French Anderson Vector particles resistant to inactivation by human serum
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
WO1994012649A2 (en) 1992-12-03 1994-06-09 Genzyme Corporation Gene therapy for cystic fibrosis
DE4242396C2 (de) 1992-12-09 1995-01-05 Helopharm Petrik Co Kg Aralkyldiaminderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
WO1994021665A1 (en) 1993-03-24 1994-09-29 Amylin Pharmaceuticals, Inc. Cloned receptors and methods for screening
DE69431750T2 (de) 1993-04-22 2003-04-03 Skyepharma Inc., San Diego Multivesikuläre liposomen mit verkapseltem cyclodextrin und pharmakologisch wirksamen verbindungen sowie verfahren zu deren verwendung
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
WO1995000655A1 (en) 1993-06-24 1995-01-05 Mc Master University Adenovirus vectors for gene therapy
GB9316989D0 (en) * 1993-08-16 1993-09-29 Lynxvale Ltd Binding molecules
EP0711829A3 (en) 1993-09-15 1997-07-09 Viagene Inc Recombinant alphavirus vector
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
DK0797676T3 (da) 1993-10-25 2006-04-18 Canji Inc Rekombinant adenoviral vektor og fremgangsmåder til anvendelse deraf
BR9408072A (pt) 1993-11-16 1997-08-12 Depotech Corp Vesículas com liberação controlada de ativos
JPH07196700A (ja) 1994-01-06 1995-08-01 Sando Yakuhin Kk 抗カルシトニン抗体及びその作製方法、並びに該抗体を用いたカルシトニンの測定方法
US6436908B1 (en) 1995-05-30 2002-08-20 Duke University Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
ES2297831T3 (es) 1994-05-09 2008-05-01 Oxford Biomedica (Uk) Limited Vectores retroviricos que presentan una tasa de recombinacion reducida.
WO1996005221A1 (en) 1994-08-16 1996-02-22 Human Genome Sciences, Inc. Calcitonin receptor
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
FR2732220B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les lichens et les prurits et composition obtenue
FR2732222B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour le traitement des prurits et des dysesthesies oculaires et palpebraux
FR2732221B1 (fr) * 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
FR2732598B1 (fr) 1995-04-10 1997-05-09 Oreal Utilisation de sel de metaux alcalino-terreux pour le traitement des prurits et des dysesthesies oculaires ou palpebraux
EP0737471A3 (fr) 1995-04-10 2000-12-06 L'oreal Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue
KR100654645B1 (ko) * 1995-04-27 2007-04-04 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
EP0851759A4 (en) * 1995-09-05 2000-12-06 Smithkline Beecham Corp COMPOUNDS AND RELATED METHODS
WO1997041223A1 (en) 1996-04-15 1997-11-06 The University Of Miami Molecular clone of cgrp receptor component protein and uses thereof
ATE424463T1 (de) 1996-05-06 2009-03-15 Oxford Biomedica Ltd Rekombinationsunfähige retrovirale vektoren
US5746694A (en) 1996-05-16 1998-05-05 Wilk; Peter J. Endoscope biopsy channel liner and associated method
WO1998003534A1 (en) 1996-07-23 1998-01-29 Smithkline Beecham Corporation Calcitonin gene-related peptide receptor component factor (houdc44)
US6586458B1 (en) * 1996-08-16 2003-07-01 Pozen Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
JP3734315B2 (ja) 1996-08-26 2006-01-11 株式会社小松製作所 曲げ加工方法および曲げ加工装置
WO1998009630A1 (en) * 1996-09-09 1998-03-12 Smithkline Beecham Corporation Compounds and methods
ATE266673T1 (de) 1996-09-10 2004-05-15 Boehringer Ingelheim Pharma Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
WO1998056779A1 (en) 1997-06-13 1998-12-17 Smithkline Beecham Corporation 4-sulfinyl benzamides as calcitonin gene-related peptide receptor antagonists
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US20030069231A1 (en) 1999-10-12 2003-04-10 Klaus Rudolf Modified aminoacids, pharmaceuticals containing these compounds and method for their production
WO1999018792A1 (en) 1997-10-10 1999-04-22 Johns Hopkins University Gene delivery compositions and methods
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
GB9809839D0 (en) * 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
JP2002525371A (ja) 1998-09-30 2002-08-13 メルク シャープ エンド ドーム リミテッド Ｃｇｒｐリガンドとしてのベンゾイミダゾリニルピペリジン
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1031350A1 (en) 1999-02-23 2000-08-30 Warner-Lambert Company Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain
US6313097B1 (en) * 1999-03-02 2001-11-06 Boehringer Ingelheim Pharma Kg Antagonists of calcitonin gene-related peptide
WO2000053211A2 (en) 1999-03-09 2000-09-14 University Of Southern California Method of promoting myocyte proliferation and myocardial tissue repair
US6521609B1 (en) 1999-08-10 2003-02-18 Boehringer Ingelheim Pharma Kg Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
US20020162125A1 (en) 2001-03-06 2002-10-31 Anne-Marie Salmon Methods and compositions for the modulation of neurogenic inflammatory pain and physical opiate withdrawal
ATE453661T1 (de) 2001-09-27 2010-01-15 Merck & Co Inc Isolierte dna-moleküle, die für einen humanisierten calcitonin gene-related peptide receptor kodieren, damit verwandte, nichthumane transgene tiere und assayverfahren
US6767056B2 (en) 2002-01-14 2004-07-27 Shin Yeh Enterprise Co., Ltd. Settee with a foldable tray-support unit
US7026312B2 (en) 2002-03-14 2006-04-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
DE60328195D1 (de) 2002-03-29 2009-08-13 Schering Corp Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
US7879991B2 (en) 2002-05-06 2011-02-01 Noxxon Pharma Ag CGRP binding nucleic acids
US20040110170A1 (en) 2002-05-18 2004-06-10 The Regents Of The University Of California Cloning and characterization of calcitonin gene related peptide receptors
US7345065B2 (en) 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
BRPI0311812B8 (pt) * 2002-06-05 2021-05-25 Bristol Myers Squibb Co antagonistas de receptor de peptídeo relacionado com o gene de calcitonina, composição farmacêutica e seu uso
AU2003244817B2 (en) * 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
DK1556020T3 (da) † 2002-08-12 2009-06-22 Birkir Sveinsson Anvendelse af CGRP-antagonistforbindelser til behandling af psoriasis
DE10250082A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1578799B8 (en) 2002-12-02 2011-03-23 Amgen Fremont Inc. Antibodies directed to tumor necrosis factor and uses thereof
PT2263692T (pt) 2002-12-24 2018-11-28 Rinat Neuroscience Corp Anticorpos anti-ngf e métodos de utilização dos mesmos
WO2004082602A2 (en) * 2003-03-14 2004-09-30 Merck & Co. Inc. Carboxamide spirohydantoin cgrp receptor antagonists
EP1605936B1 (en) 2003-03-14 2011-07-20 Merck Sharp & Dohme Corp. Aryl spirohydantoin cgrp receptor antagonists
WO2004082605A2 (en) * 2003-03-14 2004-09-30 Merck & Co. Inc. Bicyclic anilide spirohydantoin cgrp receptor antagonists
JP4673295B2 (ja) * 2003-03-14 2011-04-20 メルク・シャープ・エンド・ドーム・コーポレイション 単環式アニリドスピロヒダントインｃｇｒｐ受容体拮抗物質
EP1606286B1 (en) * 2003-03-14 2011-05-11 Merck Sharp & Dohme Corp. Benodiazepine spirohydantoin cgrp receptor antagonists
EP1615914B1 (en) 2003-04-15 2010-05-05 Merck Sharp & Dohme Corp. Cgrp receptor antagonists
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
WO2004097421A2 (en) 2003-04-29 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl)
JP2007523870A (ja) 2003-07-15 2007-08-23 メルク　エンド　カムパニー　インコーポレーテッド ヒドロキシピリジンｃｇｒｐ受容体拮抗薬
DE102004008261B3 (de) 2004-02-20 2005-09-29 Mtu Friedrichshafen Gmbh Verfahren zur Steuerung und Regelung einer Brennkraftmaschinen-Generator-Einheit
WO2005084672A1 (de) 2004-03-03 2005-09-15 Boehringer Ingelheim International Gmbh Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7279471B2 (en) * 2004-04-15 2007-10-09 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102004018794A1 (de) * 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
WO2005102322A1 (de) 2004-04-20 2005-11-03 Boehringer Ingelheim International Gmbh Verwendung eines cgrp-antagonisten in kombination mit einem serotonin-wiederaufnahme-hemmer zur behandlung von migräne
DE102004027912A1 (de) 2004-06-09 2005-12-29 Grünenthal GmbH Substituierte Cyclopenten-Verbindungen
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
TWI432196B (zh) 2005-01-18 2014-04-01 Euro Celtique Sa 內臟痛的治療
EP1770091A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
CA2619856A1 (en) 2005-08-25 2007-03-01 Wex Pharmaceuticals Inc. Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment
ATE458491T1 (de) 2005-08-26 2010-03-15 Univ Leland Stanford Junior Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocin
JP2009508970A (ja) 2005-09-21 2009-03-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 疼痛の局所造影および治療のためのシステム、組成物並びに方法
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
RS20080200A (sr) 2005-11-14 2009-07-15 Rinat Neuroscience Corp., Antagonistička antitela usmerena protiv kalcitonina, peptida povezanog sa genom, i postupak njihovog korišćenja
US8071770B2 (en) 2005-11-18 2011-12-06 Merck Sharp & Dohme Corp. Spirohydantoin aryl CGRP receptor antagonists
WO2007076336A1 (en) 2005-12-22 2007-07-05 Eli Lilly And Company Treatment of migraine with anti-cgrp antibodies
US7834000B2 (en) 2006-06-13 2010-11-16 Vertex Pharmaceuticals Incorporated CGRP receptor antagonists
WO2008011190A1 (en) 2006-07-21 2008-01-24 Vertex Pharmaceuticals Incorporated Cgrp receptor antagonists
US8293239B2 (en) 2008-03-04 2012-10-23 Pfizer Limited Methods of treating chronic pain
MX2010009724A (es) 2008-03-04 2010-09-28 Pfizer Ltd Procedimientos de tratamiento del dolor inflamatorio-.
WO2010006168A2 (en) 2008-07-09 2010-01-14 University Of Rochester Methods of treating cancer using and agent that modulates activity of the calcitonin-gene related peptide ("cgrp") receptor
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
CA2771186C (en) 2009-08-28 2018-01-02 Rinat Neuroscience Corporation Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
AR081434A1 (es) 2010-06-10 2012-08-29 Lilly Co Eli Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
RS58621B1 (sr) 2011-05-20 2019-05-31 Alderbio Holdings Llc Anti-cgrp kompozicije i njihova upotreba
NZ732970A (en) 2011-05-20 2022-08-26 H Lundbeck As Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
EP3324376A1 (en) 2012-10-29 2018-05-23 NetEnt Product Services Ltd. Architecture for multi-player, multi-game, multi- table, multi-operator & multi-jurisdiction live casino gaming
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
KR102274964B1 (ko) 2014-03-21 2021-07-09 테바 파마슈티컬스 인터내셔널 게엠베하 칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법

Also Published As

Publication number Publication date
US9884907B2 (en) 2018-02-06
PT3045182T (pt) 2018-06-05
US20150050267A1 (en) 2015-02-19
US20150361173A1 (en) 2015-12-17
CA2626120C (en) 2012-12-04
LUC00126I2 (Direct) 2019-12-27
US9346881B2 (en) 2016-05-24
RS57194B1 (sr) 2018-07-31
ZA200803484B (en) 2009-03-25
HRP20180753T1 (hr) 2018-08-24
US20170081395A1 (en) 2017-03-23
EP2380592A3 (en) 2012-06-06
RS57192B1 (sr) 2018-07-31
PT2380592T (pt) 2018-06-06
PL1957106T5 (pl) 2019-11-29
UA94244C2 (ru) 2011-04-26
ES2664854T3 (es) 2018-04-23
US20140147438A1 (en) 2014-05-29
BE2019C521I2 (Direct) 2025-12-10
HK1125837A1 (en) 2009-08-21
EA015526B1 (ru) 2011-08-30
PL3045182T3 (pl) 2018-07-31
PT1957106E (pt) 2013-12-26
ES2433251T5 (es) 2020-03-13
US9890211B2 (en) 2018-02-13
CN103421114B (zh) 2017-09-22
BRPI0618705A2 (pt) 2011-09-06
US20150361171A1 (en) 2015-12-17
BRPI0618705B1 (pt) 2018-02-06
CA2626120A1 (en) 2007-05-18
LTPA2019015I1 (lt) 2019-08-26
CN101309704B (zh) 2012-10-10
TNSN08213A1 (fr) 2009-10-30
EP3178493A1 (en) 2017-06-14
US9115194B2 (en) 2015-08-25
JP2009515942A (ja) 2009-04-16
NZ568237A (en) 2011-11-25
EP1957106B1 (en) 2013-10-16
NO344099B1 (no) 2019-09-02
EP3045182B1 (en) 2018-03-07
ECSP088451A (es) 2008-07-30
EP3842458A1 (en) 2021-06-30
WO2007054809A3 (en) 2007-08-09
NO2019043I1 (no) 2019-12-09
SI1957106T2 (sl) 2019-09-30
EP1957106B2 (en) 2019-07-24
DK3045182T3 (en) 2018-03-19
NL300997I1 (nl) 2019-07-03
US20170240625A1 (en) 2017-08-24
US10329343B2 (en) 2019-06-25
US20120009192A1 (en) 2012-01-12
CU20080088A7 (es) 2012-06-21
EP1957106A2 (en) 2008-08-20
US9884908B2 (en) 2018-02-06
US20160168244A1 (en) 2016-06-16
US20150361172A1 (en) 2015-12-17
KR20080068062A (ko) 2008-07-22
KR20110114705A (ko) 2011-10-19
IL190876A (en) 2012-06-28
US8597649B2 (en) 2013-12-03
HUE036940T2 (hu) 2018-08-28
IL190876A0 (en) 2008-11-03
AU2006313434A1 (en) 2007-05-18
US20130216535A1 (en) 2013-08-22
CY2019019I1 (el) 2019-11-27
US20150291690A1 (en) 2015-10-15
GEP20115333B (en) 2011-11-25
IL219503A0 (en) 2012-06-28
SV2008002905A (es) 2011-07-05
HUE036944T2 (hu) 2018-08-28
EP2380592B1 (en) 2018-03-07
ES2433251T3 (es) 2013-12-10
KR101250049B1 (ko) 2013-04-04
LT2380592T (lt) 2018-05-10
NO20190202A1 (no) 2008-05-19
NO344605B1 (no) 2020-02-10
US9266951B2 (en) 2016-02-23
CY1120249T1 (el) 2019-07-10
HK1225627B (en) 2017-09-15
MA30136B1 (fr) 2009-01-02
LUC00119I2 (Direct) 2020-07-10
US20170240622A1 (en) 2017-08-24
HUS1900035I1 (hu) 2019-07-29
DK2380592T3 (en) 2018-03-19
US20200247878A1 (en) 2020-08-06
US8734802B1 (en) 2014-05-27
WO2007054809A2 (en) 2007-05-18
US20170240623A1 (en) 2017-08-24
CY2019019I2 (el) 2019-11-27
US20220056114A1 (en) 2022-02-24
LUC00119I1 (Direct) 2019-05-15
CN101309704A (zh) 2008-11-19
LT3045182T (lt) 2018-05-10
NL300997I2 (nl) 2019-11-28
HRP20180752T1 (hr) 2018-06-15
US9365648B1 (en) 2016-06-14
US9890210B2 (en) 2018-02-13
DK1957106T3 (da) 2013-11-04
US9328168B2 (en) 2016-05-03
EA200801094A1 (ru) 2008-10-30
ES2664421T3 (es) 2018-04-19
CU23872B1 (es) 2013-03-27
MY153249A (en) 2015-01-29
NO20081854L (no) 2008-05-19
CN103421114A (zh) 2013-12-04
LUC00126I1 (Direct) 2019-07-09
US20090220489A1 (en) 2009-09-03
US20190092841A1 (en) 2019-03-28
PL2380592T3 (pl) 2018-07-31
US8007794B2 (en) 2011-08-30
RS20080200A (sr) 2009-07-15
JP5123197B2 (ja) 2013-01-16
SI3045182T1 (en) 2018-08-31
AU2006313434B2 (en) 2011-10-27
CY1120267T1 (el) 2019-07-10
EP3045182A1 (en) 2016-07-20
PL1957106T3 (pl) 2014-03-31
US8586045B2 (en) 2013-11-19
EP3069731A1 (en) 2016-09-21
SI1957106T1 (sl) 2014-02-28
CR9975A (es) 2008-06-02
US20240158481A1 (en) 2024-05-16
US20180162931A1 (en) 2018-06-14
SI2380592T1 (en) 2018-06-29
US9340614B2 (en) 2016-05-17
AP2008004467A0 (en) 2008-06-30
LTC2380592I2 (lt) 2020-05-11
DK1957106T4 (da) 2019-10-28
IL248025A0 (en) 2016-11-30
EP2380592A2 (en) 2011-10-26
US20170240624A1 (en) 2017-08-24
ME00419B (me) 2011-10-10

Similar Documents

Publication Publication Date Title
BRPI0618705B8 (pt) anticorpos antagonistas humanizados direcionados contra peptídeo relacionado ao gene da calcitonina, composição farmacêutica e uso dos mesmos
BR112016021423A2 (pt) anticorpos antagonistas direcionados contra peptídeo relacionado ao gene de calcitonina e métodos que utilizam o mesmo
WO2007089753A3 (en) Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof
BRPI0818765A8 (pt) Polipeptídeo, anticorpo ou seu fragmento de ligação de antígeno, polinucleotídeo, célula hospedeira, vetor, composição, uso e método para produzir polipeptídeo
BR112013020500A2 (pt) anticorpo isolado, recombinante ou purificado
NO20073981L (no) Criptobindende molekyler
NO20091926L (no) Anti-Notch3-agonist-antistoffer og deres anvendelse ved behandlingen av Notch3-relaterte sykdommer
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
BRPI0506771A (pt) anticorpo, e, composição farmacêutica
BR112016002614B8 (pt) Imunocitoquina e composição farmacêutica
WO2009071696A3 (en) Humanized antibody molecules specific for il-31
BR112012005713A2 (pt) vacinas direcionadas a célula langerhans.
BRPI0919377A2 (pt) anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
MA32031B1 (fr) Procedes et compositions faisant appel a des polypeptides de fusion klotho-fgf
BRPI0816117B8 (pt) anticorpo monoclonal isolado ou fragmento do mesmo, composiçãofarmacêutica, kit para tratamento de desordens relacionadas com colesterol, e, uso de uma proteína de ligação de antígeno ou de um anticorpo monoclonal ou fragmento do mesmo
CU20120095A7 (es) Antagonistas de pcsk9
MX2010004660A (es) NUEVOS ANTICUERPOS ESPECIFICOS DE LOS PEPTIDOS ß-AMILOIDES Y SUS USOS COMO AGENTES DE DIAGNOSTICO Y DROGAS.
PE20091713A1 (es) Inhibicion del receptor para la proteina estimulante del macrofago (ron), composiciones y metodos
BR112015010817A8 (pt) anticorpos anti-hemaglutinina isolado, método de tratamento, inibição ou prevenção de infecções, composição, composição farmacêutica, ácido nucleico isolado, célula hospedeira, método de produção de anticorpos e uso do anticorpo anti-hemaglutinina
BR112012010266A2 (pt) anticorpo anti-fractalquina ou fragmento de ligação a fkn do mesmo, composição farmacêutica, ácido nucleico, vetor, célula hospedeira, métodos para preparar um anticorpo anti-fractalquina ou fragmento de ligação a fkn do mesmo, e para tratar um distúrbio inflamatório, e, uso de um anticorpo ou fragmento de ligação a fkn do mesmo
BRPI0919236A8 (pt) Terapêutica e vacinas de combinação de gas
CR20220660A (es) Métodos para tratar o prevenir infecciones por sars-cov2 y covid-19 con anticuerpos de glicoproteína espícular anti-sars-cov-2
EA201170795A1 (ru) Антагонисты ccr2 группы 4-азетидинил-1-гетероарил-циклогексанола
MY160435A (en) A novel antiviral peptide against avian influenza virus h9n2
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: REF. A RPI NO 2150 DE 20/03/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B25A Requested transfer of rights approved
B25A Requested transfer of rights approved
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/11/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF